Prevalence of Nosocomial Venous Thromboembolic Complications in New Tuberculosis Patients and Relapses: Data from the Moscow City Registry (A Multicenter Study)

The objective: to evaluate VTEC in new tuberculosis patients and relapses, to determine main factors influencing its development (according to data of the patients admitted to Moscow tuberculosis hospitals)

Subjects and Methods. Based on the data of epidemiological tuberculosis monitoring system of Moscow, treatment outcomes of 4609 tuberculosis patients admitted to tuberculosis hospitals from 2020 to 2022 were retrospectively analyzed. The incidence of VTEC was estimated.

Results. Totally 214/4609 cases of VTEC were identified (4.6%; 95% CI 4.1-5.3%), among which the incidence of DVT made 3.5% (95% CI 3.0-4.1%), SVP 1.5% (95% CI 1.2-1.9%), and PATE 0.6% (95% CI 0.4-0.8%). The most significant risk factors of thrombotic complications in tuberculosis patients were identified, those factors included HIV infection (RR 3.8; 95% CI 2.7-4.5) and fibrous cavernous form of pulmonary tuberculosis (RR 9.1; 95% CI 4.7-17.6). The overall prevalence of VTEC in tuberculosis hospitals was 3 or more times higher than in general clinics (according to the published data).

Conclusion. The data obtained indicate that patients hospitalized for pulmonary tuberculosis face a high risk of VTEC development that requires prediction and prevention.

1. Belilovsky E.M., Borisov S.E. Organization of epidemiological monitoring of tuberculosis in the city of Moscow. Problemy Sotsialnoy Gigieny, Zdravookhraneniya i Istorii Meditsiny, 2021, vol. 29, no. S2, pp. 1275-1280. (In Russ.) https://doi.org/10.32687/0869-866X-2021-29-s2-1275-1280

2. Zabolevayemost vsego naseleniya Rossii v 2016 g. Statisticheskiye materialy. Chast II. [Incidence of the entire population of Russia in 2016. Statistical materials. Part II]. 2017. Available: https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskie-iinformatsionnye-materialy/statisticheskiysbornik-2016-god Accessed January 28, 2023

3. Lobastov K.V., Dementieva G.I., Laberko L.A. Current insights on the etiology and pathogenesis of venous thrombosis: virchow’s triad revision. Flebologiya, 2019, vol. 13, no. 3, pp. 227-235. (In Russ.) https://doi.org/10.17116/flebo201913031227

4. Ftiziatriya. Natsionalnoye rukovodstvo. [Phthisiology. National Guidelines]. M.I. Perelman, eds., Moscow, GEOTAR-Media Publ., 2007, 512 p.

5. Allaert F.A., Benzenine E., Quantin C. Hospital incidence and annual rates of hospitalization for venous thromboembolic disease in France and the USA. Phlebology, 2017, vol. 32, no. 7, pp. 443-447. https://doi.org/10.1177/0268355516653005

6. Alvaro-Meca A., Ryan P., Martínez-Larrull E., Micheloud D., Berenguer J., Resino S. Epidemiological trends of deep venous thrombosis in HIV-infected subjects (1997-2013): A nationwide population-based study in Spain. European Journal of Internal Medicine, 2018, no. 48, pp. 69-74. https://doi.org/10.1016/j.ejim.2017.10.012

7. Bibas M., Biava G., Antinori A. HIV-associated venous thromboembolism. Mediterranean Journal of Hematology and Infectious Diseases, 2011, vol. 3, no. 1, pp. e2011030. https://doi.org/10.4084/MJHID.2011.030

8. Cafaro A., Barillari G., Moretti S., Palladino C., Tripiciano A., Falchi M., Picconi O., Pavone Cossut M.R., Campagna M., Arancio A., Sgadari C., Andreini C., Banci L., Monini P., Ensoli B. HIV-1 Tat protein enters dysfunctional endothelial cells via integrins and renders them permissive to virus replication. International Journal of Molecular Sciences, 2020, vol. 22, no. 1, pp. 317. https://doi.org/10.3390/ijms22010317

9. Elmi G., Aluigi L., Allegri D., Rinaldi E.R., Camaggi V., Di Giulio R., Martignani A., Bacchi Reggiani M.L., Domanico A., Antignani P.L. Calf deep vein thrombosis: frequency, therapeutic management, early outcomes and all-causes mortality in a cohort of hospitalized patients. International Angiology: Journal of the International Union of Angiology, 2020, vol. 39, no. 6, pp. 467-476. https://doi.org/10.23736/S0392-9590.20.04528-9

10. Folsom A.R., Cushman M., Tsai M.Y., Heckbert S.R., Aleksic N. Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. American Journal of Hematology, 2002, vol. 71, no. 4, pp. 285-290. https://doi.org/10.1002/ajh.10229

11. Goncalves I.M., Alves D.C., Carvalho A., do Ceu Brito M., Calvario F., Duarte R. Tuberculosis and venous thromboembolism: a case series. Cases Journal, 2009, vol. 16, no. 2, pp. 9333. https://doi.org/10.1186/1757-1626-2-9333

12. Kahn S.R., Lim W., Dunn A.S., Cushman M., Dentali F., Akl E.A., Cook D.J., Balekian A.A., Klein R.C., Le H., Schulman S., Murad M.H. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, vol. 141 (2 suppl.), pp. e195S–e226S. https://doi.org/10.1378/chest.11-2296

13. Khan F., Tritschler T., Kahn S.R., Rodger M.A. Venous thromboembolism. Lancet, 2021, vol. 398, no. 10294, pp. 64-77. https://doi.org/10.1016/S0140-6736(20)32658-1

14. Khanna R., Maynard G., Sadeghi B., Hensley L., Medvedev S., Danielsen B., White R.H. Incidence of hospital-acquired venous thromboembolic codes in medical patients hospitalized in academic medical centers. Journal of Hospital Medicine, 2014, vol. 9, no. 4, pp. 221-225. https://doi.org/10.1002/jhm.2159

15. Law Y., Chan Y.C., Cheng S.W.K. Epidemiological updates of venous thromboembolism in a Chinese population. Asian Journal of Surgery, 2018, vol. 41, no. 2, pp. 176-182. https://doi.org/10.1016/j.asjsur.2016.11.005

16. Minardi M.L., Fato I., Di Gennaro F., Mosti S., Mastrobattista A., Cerva C., Libertone R., Saracino A., Goletti D., Girardi E., Andreoni M., Palmieri F., Gualano G. Common and rare hematological manifestations and adverse drug events during treatment of active TB: a state of art. Microorganisms, 2021, vol. 9, no. 7, pp. 1477. https://doi.org/10.3390/microorganisms9071477

17. Perkins M.V., Joseph S.B., Dittmer D.P., Mackman N. Cardiovascular disease and thrombosis in HIV infection. Arteriosclerosis, Thrombosis and Vascular Biology, 2023, vol. 43, no. 2, pp. 175-191. https://doi.org/10.1161/ATVBAHA.122.318232

18. Prchal J.T. Hypoxia and thrombosis. Blood, 2018, vol. 132, no. 4, pp. 348-349. https://doi.org/10.1182/blood-2018-06-854976

19. Schmidt M., Horvath-Puho E., Thomsen R.W., Smeeth L., Sørensen H.T. Acute infections and venous thromboembolism. Journal of Internal Medicine, 2012, vol. 271, no. 6, pp. 608–618. https://doi.org/10.1111/j.1365-2796.2011.02473.x

20. Turken O., Kunter E., Sezer M., Solmazgul E., Cerrahoglu K., Bozkanat E., Ozturk A., Ilvan A. Hemostatic changes in active pulmonary tuberculosis. The International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union against Tuberculosis and Lung Disease, 2002, vol. 6, no. 10, pp. 927-932.

21. Wendelboe A.M., Raskob G.E. Global burden of thrombosis: epidemiologic aspects. Circulation Research, 2016, vol. 118, no. 9, pp. 1340-1347. https://doi.org/10.1161/CIRCRESAHA.115.306841